Eltrombopag Plus Cyclosporin A Show Activity as First-Line Treatment of Aplastic Anemia
A study published in Lancet Hematology showed promising results for using eltrombopag and cyclosporin A as first-line treatment for severe aplastic anemia. The multicenter phase 2 trial treated 54 patients with severe AA and found a 6-month hematologic overall response rate of 46%, with a complete response rate of 4%. The most common adverse events…